Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLA-mismatched allogeneic HSCT with low-dose alemtuzumab for standard-risk advanced hematological disease
jRCTs031180238Completed
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of alemtuzumab in Acute Leukaemia, chronic myelogenous leukemia (CML), lymphosarcoma and 4 more. Primary endpoint: Disease-free survival at 1 year. Started Oct 2015; status: completed.
02
Drugs
alemtuzumab
03
Conditions
Acute Leukaemiachronic myelogenous leukemia (CML)lymphosarcomamyelodysplastic syndrome (MDS)adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on jRCTs031180238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180238.